Drugs Rules, 1945 Amendment: Uniform regulation for cell and gene therapies

Why in News?

The Central Government has amended the Drugs Rules, 1945 to bring advanced cell and gene therapy products under a single, uniform regulatory regime. The Ministry of Health and Family Welfare notified the change through a Gazette Notification, confirmed by PIB.

The amendment places cell or stem cell derived products, gene therapeutic products and xenografts under the Centrally License Approving Authority (CLAA) framework, meaning joint Centre-State licensing oversight rather than uneven, state-by-state approval.

It expands a list that already held vaccines, large volume parenterals and r-DNA medicines, extending the same high-scrutiny gate to the newest classes of frontier therapy.

• Amendment issued under the Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945.
• Three new categories added to CLAA: cell/stem cell derived products, gene therapeutics, xenografts.
• Named examples include CAR-T cell therapy for blood cancers and gene editing products for genetic disorders.
• Existing CLAA list already covered vaccines, large volume parenterals (IV solutions above 100 ml) and r-DNA based medicines.
• PIB called these highly complex, specialised and rapidly evolving areas that need enhanced scrutiny for patient safety.
• Detailed rules published via Gazette Notification on egazette.gov.in for public reference.

The development matters in the context of:

• India lacked a uniform national standard for licensing these fast-evolving therapies, risking inconsistent state-level approvals.
• The move signals regulatory readiness for advanced therapy medicinal products (ATMPs) as domestic biotech scales up.
• It matters for affordable access: India’s first indigenous CAR-T therapy is positioned at a fraction of Western prices.
• It links directly to India’s ambition, under the BioE3 policy, to become a global hub for high-value biomanufacturing.

UPSC Relevance

Prelims Relevance

• Drugs and Cosmetics Act, 1940 and Drugs Rules, 1945 as the parent legislation.
• Centrally License Approving Authority (CLAA) — joint Centre-State licensing mechanism.
• CDSCO (Central Drugs Standard Control Organisation) and the DCGI as central regulator.
• New Drugs and Clinical Trials Rules, 2019 — the clinical-trial and new-drug approval regime.
• CAR-T cell therapy — Chimeric Antigen Receptor T-cell therapy for leukemias and lymphomas.
• NexCAR19 — India’s first indigenous CAR-T therapy (ImmunoACT, IIT Bombay-Tata Memorial Centre).
• Xenografts — animal tissue-derived products such as heart valves.
• r-DNA (recombinant DNA) based medicines and large volume parenterals.
• Difference between gene replacement and gene editing therapeutics.
• BioE3 policy (Biotechnology for Economy, Environment and Employment).
• State Licensing Authorities vs Central Licensing Authority roles under the Act.

Mains Relevance

GS Paper 3

• Regulation of emerging biotechnologies and the balance between innovation and patient safety.
• Developments in science and technology and their applications in healthcare and life sciences.
• Indigenisation of technology and building an affordable domestic biopharma base.

GS Paper 2

• Government policies and interventions in the health sector, and issues in centre-state regulatory coordination.
• Issues relating to development and management of the health sector and access to affordable care.

Essay

• Science must serve the many, not the few: regulating frontier medicine for equity.
• Innovation and oversight: the state as an enabler of safe technology adoption.

Background and Context

The regulatory architecture behind the news

The amendment works within India’s long-standing drug law, not a new statute.

• The Drugs and Cosmetics Act, 1940 and Drugs Rules, 1945 govern import, manufacture, distribution and sale of drugs in India.
• Most routine drug licensing is done by State Licensing Authorities, but critical, high-risk categories fall under joint Centre-State control.
• That joint mechanism is the Centrally License Approving Authority (CLAA) scheme, coordinated through the CDSCO under the Drugs Controller General of India (DCGI).
• Before this change, CLAA covered vaccines, large volume parenterals (IV fluids above 100 ml) and r-DNA based medicines.
• The amendment expands, rather than replaces, this list — the parent Act and the state role stay intact.

What cell and gene therapy actually means

These are living or biologically active products, a class apart from ordinary chemical drugs.

• Cell and gene therapies treat disease by adding, editing, replacing or delivering living cells and genetic material, rather than a small-molecule pill.
• CAR-T therapy (Chimeric Antigen Receptor T-cell) re-engineers a patient’s own T-cells to recognise and kill cancer cells, used against leukemias and lymphomas.
• Gene replacement inserts a healthy copy of a faulty gene; gene editing (tools such as CRISPR) rewrites the DNA sequence itself to correct inherited disorders.
• Xenografts are animal tissue-derived products — for example heart valves — transplanted into humans, with use in cardiology and orthopedics.
• Many are one-time, personalised, living-drug treatments, which makes their manufacture, storage and quality control far harder than for standard medicines.
• Unlike a mass-produced tablet, a CAR-T dose is often made patient by patient, so quality assurance must cover each individual batch.

What the amendment actually adds

Three advanced product classes now need central-plus-state clearance.

• Cell or stem cell derived products — including stem cell-based regenerative treatments and CAR-T cell therapies.
• Gene therapeutic products — covering both gene replacement and gene editing products.
• Xenografts — animal tissue-derived products such as heart valves transplanted into humans.
• All three are folded into the existing CLAA list, so a single uniform standard applies nationwide.
• Licensing now needs the sign-off of both Central and State Licensing Authorities, raising the bar of scrutiny before a product reaches patients.

India's regulatory ecosystem for biologics

The amendment plugs into an existing web of guidelines and bodies.

• The CDSCO, headed by the DCGI, is the apex central drug regulator for approvals, imports and standards.
• The New Drugs and Clinical Trials Rules, 2019 govern how new drugs — including biologics — are trialled and approved in India.
• The National Guidelines for Stem Cell Research (2017), issued jointly by ICMR and DBT, set ethics norms and bar unproven stem-cell ‘treatments’.
• The National Guidelines for Gene Therapy Product Development and Clinical Trials (2019) from CDSCO, ICMR and DBT frame research on gene therapies.
• Guidelines alone are advisory; folding these products into CLAA makes compliance a condition of the manufacturing licence itself.
• This amendment gives those guidelines a firmer statutory licensing anchor under the Drugs Rules, closing the gap between guidance and enforceable law.

Why these therapies need extra scrutiny

They are complex, living or biologically active products with real clinical risk.

• CAR-T therapy can trigger severe immune reactions such as cytokine release syndrome, needing specialised centres to manage.
• Gene therapies alter or replace genes and carry long-term, sometimes irreversible, safety questions that surface only over years.
• Xenografts raise risks of immune rejection and cross-species infection, needing tight sourcing and processing norms.
• Unproven stem-cell clinics have long marketed dubious cures in India, making a hard licensing gate important for public safety.
• Poor manufacturing controls in a living-cell product can seed contamination or wrongly engineered cells, harm that no recall can undo once infused.
• PIB noted these are highly complex, specialised and rapidly evolving areas that demand enhanced oversight for patient safety.

Why uniform regulation matters

The core gain is one national standard instead of many.

• Joint oversight by Central and State Licensing Authorities replaces uneven, state-by-state treatment.
• It removes the risk of a therapy being approved to different standards in different states — a real danger given fragmented past practice.
• It raises regulatory rigour for emerging technologies while keeping a predictable, single pathway for manufacturers.
• A common standard makes Indian approvals easier to benchmark against global regulators and to trust for export.
• PIB framed the step as aligning India with global best practices in advanced-therapy regulation.

The affordability and self-reliance angle

Regulation also shapes access, not just safety.

• India’s first indigenous CAR-T, NexCAR19, was developed by ImmunoACT, incubated at IIT Bombay with Tata Memorial Centre, and cleared by CDSCO in October 2023.
• It is priced at roughly one-tenth of imported CAR-T therapies — about ₹30-42 lakh against imported options that can run into crores abroad.
• A clear central pathway supports domestic manufacturing and quicker, safer adoption of new treatments made in India.
• It fits the broader push for self-reliance in high-value biopharma and life sciences, and the BioE3 policy‘s aim of a biomanufacturing-led economy.
• Local production also shortens the wait for patients, since imported living-cell products face cold-chain and logistics delays that can be fatal in aggressive cancers.
• The government cast the move as safeguarding public health while promoting innovation.

How the world regulates advanced therapies

Major regulators already run dedicated pathways for these products.

• The US FDA uses the RMAT (Regenerative Medicine Advanced Therapy) designation to fast-track cell and gene therapies with early evidence of benefit.
• The European Medicines Agency (EMA) regulates them as ATMPs (Advanced Therapy Medicinal Products) through a specialist committee.
• These frameworks pair expedited review with long-term follow-up and registries to catch delayed side-effects.
• India’s move brings it closer to this global template of specialised, central oversight for frontier medicine.
• Both regulators also demand rigorous manufacturing and comparability data for each product, a benchmark India’s assessors will now have to apply.
• The gap ahead is not the rulebook but assessor capacity and post-market surveillance to match these systems.

Where challenges remain

A rulebook is only as good as the capacity to enforce it.

• Regulators need trained assessors and lab capacity to evaluate living-cell and gene-editing products.
• Ethical guardrails on germline vs somatic gene editing and informed consent remain a live policy question.
• Costs, cold-chain logistics and hospital infrastructure limit real-world access even after approval.
• A single national licence must not become a bottleneck that slows down affordable domestic innovation.
• Many state drug regulators still lack staff skilled in biologics, so the joint-oversight model works only if the Centre carries most of the technical load.
• Coordination between CDSCO, state authorities and research bodies like ICMR and DBT will decide implementation quality.

Way Forward

Build regulatory capacity

• Strengthen CDSCO assessor teams and specialised labs for cell and gene product evaluation.
• Issue clear technical guidelines and standard operating protocols for each new category, so approvals are fast and predictable.

Protect access and ethics

• Support indigenous affordable therapies like NexCAR19 so uniform rules do not become a cost barrier.
• Set transparent ethical norms for gene editing, sourcing of xenografts and informed consent, aligned with ICMR-DBT guidelines.

Track outcomes

• Build pharmacovigilance and long-term patient registries for these one-time, high-cost interventions.
• Link domestic capacity to the BioE3 policy so regulation and manufacturing scale together.

Pair the tighter licensing regime with insurance and public-financing options, so uniform national standards translate into real access for patients rather than a paper safeguard.

Conclusion

The amendment to the Drugs Rules, 1945 is a quiet but consequential upgrade. It treats cell, gene and xenograft therapies as the high-risk frontier medicine they are, and gives them a single national standard through the CLAA framework.

By anchoring earlier ICMR-DBT guidelines in enforceable licensing, and by aligning with the FDA and EMA template, India signals it is ready to host the next generation of therapeutics safely.

Done well, it can make India both safer and more self-reliant in advanced therapeutics. The real test now shifts from notification to enforcement capacity, affordability and ethics.

UPSC Practice Questions

Prelims MCQ 1

With reference to the recent amendment to the Drugs Rules, 1945, consider the following statements:

1. It brings cell or stem cell derived products under the Centrally License Approving Authority framework.
2. It removes vaccines from central licensing oversight.
3. Xenografts are now included within the same framework.

How many of the above statements are correct?

(a) Only one (b) Only two (c) All three (d) None

Answer: (b) Only two

Explanation:

Statements 1 and 3 are correct. Statement 2 is wrong — vaccines were already under CLAA and continue to be; the amendment adds new categories rather than removing any.

Prelims MCQ 2

The Centrally License Approving Authority (CLAA) mechanism is best described as:

(a) A purely state-level drug licensing body (b) A joint Centre-State licensing framework for specified critical products (c) A private accreditation agency for hospitals (d) A World Health Organization certification scheme

Answer: (b) A joint Centre-State licensing framework for specified critical products

Explanation:

Under the Drugs and Cosmetics Act, CLAA provides joint oversight by Central and State Licensing Authorities for high-risk categories like vaccines, r-DNA medicines and now cell, gene and xenograft products.

UPSC Mains Questions

1. The regulation of cell and gene therapies tests a government’s ability to balance patient safety with rapid innovation. In this light, examine the significance of bringing these therapies under India’s uniform licensing framework. (250 words)
2. Advanced therapies such as CAR-T offer transformative outcomes but raise concerns of cost, ethics and access. Discuss how India can regulate frontier medicine without deepening health inequity. (250 words)
3. ‘Statutory licensing gives teeth to scientific guidelines.’ Analyse this statement with reference to India’s evolving framework for advanced therapy medicinal products. (150 words)

Source: PIB, Ministry of Health and Family Welfare.

Frequently Asked Questions

PDF